Guardant Health is a leading precision oncology company transforming cancer care through the power of liquid biopsy. With over 500,000 blood tests performed by 12,000 doctors to date, the company provides critical insights that help clinicians discover cancer early and select the best treatment paths. Guardant's proprietary blood tests span all stages of cancer - from screening to advanced disease - and have achieved historic milestones, including securing the first FDA-approved blood tests for comprehensive genomic testing and primary colorectal cancer screening. The Shield test represents a breakthrough in cancer detection, offering a convenient blood draw option that has been approved for adults 45 and older at average risk for colorectal cancer.
Beyond diagnostics, Guardant Health enables biopharma partners to accelerate drug development through advanced genomic profiling and real-world evidence. Founded in 2012 and headquartered in Palo Alto, California, the company operates globally with teams across the Americas, Europe, Asia, Middle East, and Africa. Guardant's mission to conquer cancer with data drives every aspect of their work, from developing breakthrough tests like Guardant360 CDx and Guardant Reveal to maintaining rigorous quality standards in their CLIA-certified, CAP-accredited laboratories. Their comprehensive approach spans cancer screening, early-stage detection, advanced cancer management, and biopharma solutions - all focused on giving patients more time free from cancer.